Igg International Inc Sample Contracts

RECITALS:
Consulting Agreement • November 14th, 1996 • Igg International Inc • Services-commercial physical & biological research • Massachusetts
AutoNDA by SimpleDocs
WARRANT -------
Warrant Agreement • May 3rd, 2001 • Safescience Inc • Biological products, (no disgnostic substances)
WARRANT -------
Warrant Agreement • April 7th, 2000 • Safescience Inc • Services-commercial physical & biological research
BETWEEN
License Agreement • June 29th, 2001 • Safescience Inc • Biological products, (no disgnostic substances) • New York
AND
Termination Agreement • April 11th, 2003 • Glycogenesys Inc • Biological products, (no disgnostic substances) • New York
Exhibit 4.1 -----------
Subscription Agreement • October 22nd, 2001 • Safescience Inc • Biological products, (no disgnostic substances) • Massachusetts
SECURITIES PURCHASE AGREEMENT
Securities Purchase Agreement • April 7th, 2000 • Safescience Inc • Services-commercial physical & biological research • Nevada
WARRANT -------
Warrant Agreement • April 7th, 2000 • Safescience Inc • Services-commercial physical & biological research
DAYMON ASSOCIATES, INC.
Partnership Agreement • April 28th, 2000 • Safescience Inc • Services-commercial physical & biological research
14- DO NOT SIGN WITHOUT READING THIS AGREEMENT IN ITS ENTIRETY
Subscription Agreement • January 22nd, 2004 • Glycogenesys Inc • Biological products, (no disgnostic substances) • Massachusetts
REGISTRATION RIGHTS AGREEMENT
Registration Rights Agreement • October 24th, 2005 • Glycogenesys Inc • Biological products, (no disgnostic substances) • Nevada

REGISTRATION RIGHTS AGREEMENT (this "Agreement"), dated as of October 21, 2005, by and between GLYCOGENESYS, INC., a Nevada corporation, (the "Company"), and FUSION CAPITAL FUND II, LLC (together with it permitted assigns, the “Buyer”). Capitalized terms used herein and not otherwise defined herein shall have the respective meanings set forth in the Common Stock Purchase Agreement by and between the parties hereto, dated as of the date hereof (as amended, restated, supplemented or otherwise modified from time to time, the "Purchase Agreement").

RECITALS
License Agreement • January 31st, 2001 • Safescience Inc • Services-commercial physical & biological research • Michigan
RECITALS:
Securities Purchase Agreement • January 22nd, 2004 • Glycogenesys Inc • Biological products, (no disgnostic substances) • New York
ARTICLE 1 DEFINITIONS
Development and Supply Agreement • April 11th, 2003 • Glycogenesys Inc • Biological products, (no disgnostic substances) • Washington
AND
Subscription, Joint Development and Operating Agreement • June 29th, 2001 • Safescience Inc • Biological products, (no disgnostic substances) • New York
AutoNDA by SimpleDocs
COMMON STOCK PURCHASE AGREEMENT
Common Stock Purchase Agreement • October 24th, 2005 • Glycogenesys Inc • Biological products, (no disgnostic substances) • Nevada

COMMON STOCK PURCHASE AGREEMENT (the “Agreement”), dated as of October 21, 2005 by and between GLYCOGENESYS, INC., a Nevada corporation (the “Company”), and FUSION CAPITAL FUND II, LLC, an Illinois limited liability company (the “Buyer”). Capitalized terms used herein and not otherwise defined herein are defined in Section 10 hereof.

OFFICE LEASE
Office Lease • March 31st, 1998 • Safescience Inc • Services-commercial physical & biological research
AGREEMENT
Stock Compensation Agreement • November 14th, 1996 • Igg International Inc • Services-commercial physical & biological research • Massachusetts
REGISTRATION RIGHTS AGREEMENT
Registration Rights Agreement • March 8th, 2005 • Glycogenesys Inc • Biological products, (no disgnostic substances) • New York

This Registration Rights Agreement (the “Agreement”) is made and entered into as of this 4th day of March, 2005 by and among GlycoGenesys, Inc., a Nevada corporation (the “Company”), and the “Investors” named in that certain Purchase Agreement, dated March , 2005, by and among the Company and the Investors (the “Purchase Agreement”). Capitalized terms not otherwise defined herein shall have the meanings ascribed thereto in the Purchase Agreement.

Contract
Warrant Agreement • March 8th, 2005 • Glycogenesys Inc • Biological products, (no disgnostic substances) • New York

THIS WARRANT HAS NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED, OR THE SECURITIES LAWS OF ANY STATE AND MAY NOT BE SOLD, TRANSFERRED OR OTHERWISE DISPOSED OF EXCEPT PURSUANT TO AN EFFECTIVE REGISTRATION STATEMENT OR EXEMPTION FROM REGISTRATION UNDER THE FOREGOING LAWS.

STRONG RIVER INVESTMENTS, INC. C/O GONZALEZ-RUIZ & ALEMAN (BVI) LIMITED WICKHAMS CAY I, VANTERPOOL PLAZA P.O. BOX 873 ROAD TOWN, TORTOLLA. B.V.I.
Securities Purchase Agreement • April 7th, 2000 • Safescience Inc • Services-commercial physical & biological research • New York
NONQUALIFIED STOCK OPTION AGREEMENT GLYCOGENESYS, INC.
Nonqualified Stock Option Agreement • March 23rd, 2005 • Glycogenesys Inc • Biological products, (no disgnostic substances) • Massachusetts

This Agreement confirms the grant of an option to you effective (the “Effective Date”) under the GlycoGenesys, Inc. 2003 Omnibus Incentive Plan (the “Plan”), upon the terms and conditions described herein. A copy of the Plan is being furnished to you concurrently with the execution of this Agreement.

INCENTIVE STOCK OPTION AGREEMENT GLYCOGENESYS, INC.
Incentive Stock Option Agreement • March 23rd, 2005 • Glycogenesys Inc • Biological products, (no disgnostic substances) • Massachusetts

This Agreement confirms the grant of an option to you effective (the “Effective Date”) under the GlycoGenesys, Inc. 2003 Omnibus Incentive Plan (the “Plan”), upon the terms and conditions described herein. A copy of the Plan is being furnished to you concurrently with the execution of this Agreement.

MANUFACTURING SUPPLY AGREEMENT
Manufacturing Supply Agreement • May 23rd, 2005 • Glycogenesys Inc • Biological products, (no disgnostic substances) • Massachusetts

This AGREEMENT is made and entered into this 10th day of March 2005 (the “Effective Date”) by and between Johnson Matthey Pharmaceutical Materials, Inc. d/b/a Johnson Matthey Pharma Services having a principal place of business at 25 Patton Road, Devens, MA 01432, (“JMPS”) and GlycoGenesys, Inc., having a principal place of business at 31 St. James Avenue, Boston, Massachusetts 02116 (“Client”). Both JMPS and Client are referred to herein individually as “Party” and collectively as the “Parties.”

Draft better contracts in just 5 minutes Get the weekly Law Insider newsletter packed with expert videos, webinars, ebooks, and more!